5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
NEUTRAL | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 9.89▼ | 9.88▲ | 9.88▲ | 9.87▲ | 9.91▲ |
MA10 | 9.88▼ | 9.87▲ | 9.86▲ | 9.91▲ | 9.86▲ |
MA20 | 9.87▲ | 9.86▲ | 9.86▲ | 9.91▲ | 9.89▲ |
MA50 | 9.86▲ | 9.89▼ | 9.90▼ | 9.84▲ | 9.67▲ |
MA100 | 9.90▼ | 9.92▼ | 9.91▼ | 9.88▲ | 9.26▲ |
MA200 | 9.92▼ | 9.89▼ | 9.84▲ | 9.69▲ | 9.08▲ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.002▲ | 0.006▲ | 0.006▲ | -0.012▼ | -0.007▼ |
RSI | 52.240▲ | 52.348▲ | 50.330▲ | 52.718▲ | 54.039▲ |
STOCH | 66.667 | 76.861 | 74.306 | 28.889 | 86.302▲ |
WILL %R | -75.000 | -37.500 | -37.500 | -50.000 | -15.385▲ |
CCI | 25.000 | 109.479▲ | 114.583▲ | -50.554 | 52.401 |
Monday, September 29, 2025 04:16 AM
New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL monoclonal antibody CLYM116 Phase 1 trial initiation expected in Q4 2025, with ...
|
Saturday, September 27, 2025 07:13 PM
Discover why Voya Global Advantage Fund (IGA) holds a 'Hold' rating despite a high 10%+ yield, global diversification, and a narrowing discount.
|
Thursday, September 25, 2025 11:31 PM
CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) support the recent publication of the updated clinical practice guidelines for the ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
30/09/25 | 9.86 | 9.939 | 9.85 | 9.92 | 58,585 |
29/09/25 | 9.87 | 9.9097 | 9.835 | 9.86 | 94,812 |
26/09/25 | 9.85 | 9.91 | 9.83 | 9.84 | 49,700 |
25/09/25 | 9.91 | 9.94 | 9.82 | 9.86 | 59,700 |
24/09/25 | 9.95 | 9.97 | 9.88 | 9.88 | 105,800 |
23/09/25 | 9.97 | 9.97 | 9.92 | 9.97 | 65,500 |
22/09/25 | 9.95 | 9.96 | 9.92 | 9.95 | 31,500 |
19/09/25 | 9.98 | 10.02 | 9.91 | 9.94 | 94,200 |
18/09/25 | 9.96 | 10.02 | 9.94 | 9.94 | 68,700 |
17/09/25 | 9.99 | 9.99 | 9.87 | 9.96 | 44,400 |
|
|
||||
|
|
||||
|
|